ABSTRACT: Despite the existence of flu vaccines and smallmolecule antiviral drugs, influenza virus infection remains a public health concern that warrants immediate attention. As resistance to the only orally bioavailable drug, oseltamivir, has been continuously reported, there is a clear need to develop the next-generation of anti-influenza drugs. We chose the influenza A virus M2-S31N mutant proton channel as the drug target to address this need as it is one of the most conserved viral proteins and persist in >95% of currently circulating influenza A viruses. In this study, we report the development of a late-stage diversification strategy for the expeditious synthesis of M2-S31N inhibitors. The channel blockage and antiviral activity of the synthesized compounds were tested in two-electrode voltage clamp assays and antiviral assays, respectively. Several M2-S31N inhibitors were identified to have potent M2-S31N channel blockage and micromolar antiviral efficacy against several M2-S31N-containing influenza A viruses.
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The influenza virus is a negative-strand RNA virus belonging to the orthomyxoviridae family. Each influenza virion contains eight segments of RNA. Due to the lack of proofreading function of the influenza virus polymerase and the segmented nature of its RNAs, the influenza virus undergoes both antigenic drift and antigenic shift during its replication, which results in a large diversity of influenza types and subtypes. Although this is beneficial for viral adaption and evolution, it creates a grand challenge in designing antiviral drugs. Ideally, an antiviral drug should target the most conserved viral proteins or host factors such that its efficacy does not depend on strain variation. The M2-S31N proton channel is such a drug target that meets this criterion. It is one of the most conserved viral proteins among influenza A viruses. Genetic sequencing revealed that >95% of currently circulating influenza A viruses carry this mutation, rendering M2-S31N a high-profile drug target.
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M2 is a proton-selective homotetrameric channel associated with the viral membrane. 11, 12 The function of M2 is to facilitate viral uncoating during the early stage of viral replication. Additionally, in certain influenza strains, M2 also helps equilibrate the pH across the Golgi apparatus, thereby preventing premature conformational change of hemagglutinin.
13 M2 is absolutely required during viral replication: deleting the M2 gene or blocking the proton conductance of M2 using small molecules leads to inhibition of viral replication. Thus, M2 is a validated drug target. The adamantanes, such as amantadine and rimantadine, are wild-type (WT) M2 channel blockers. However, their use has been limited by prevalent drug resistance. It is important to stress that although a large number of M2 mutants were selected from cell culture, animals, and human patients upon drug treatment, only a limited number of M2 mutants evolved the fitness of transmission among humans, namely, V27A, S31N, and L26F.
14,15 Among these, S31N is the most prevalent mutant and persists in the majority of currently circulating influenza A viruses, including the pandemic A/ California/07/2009 (H1N1) strain and the recently emerged A/Switzerland/9715293/2013 (H3N2) strain in North America. 16 Propelled by mechanistic studies of the proton conductance and drug inhibition mechanisms by X-ray crystallography, 17−23   NMR,  19−21 and molecular dynamics simulations,  24,25 recent  years have witnessed steady progress toward designing  inhibitors targeting M2-S31N, 10 which was previously considered undruggable despite decades of traditional medicinal chemistry efforts. The pharmacophore of M2-S31N channel blockers consists of a hydrophobic template such as adamantane, a positively charged ammonium linker, and an aromatic headgroup with a hydrophobic substitution ( Figure  1) . 21, 26, 27 It has been found that the adamantane template and the ammonium linker are essential for M2-S31N inhibition. Substituting adamantane with other hydrophobic cage structures leads to a decrease of M2-S31N channel inhibition. In contrast, diverse aromatic head groups with either cyclic or acyclic hydrophobic substitutions are tolerated ( Figure 1B) . In this study, to provide additional structurally diverse lead compounds for in vivo animal studies, we examined the structure−activity relationships (SARs) of M2-S31N inhibitors by diversifying the aromatic head groups and the hydrophobic substitutions ( Figure 1D ). We devised an expeditious synthesis strategy that enables us to diversify the hydrophobic substitutions at the last step, which greatly facilitates lead optimization. Synthesized compounds were tested in both electrophysiological assays and antivirals assays. This effort led to several lead compounds with potent channel blockage and single micromolar antiviral efficacy as well as high selectivity.
■ RESULTS AND DISCUSSION
Chemistry. In the present study, the goal is to optimize the channel blockage potency of M2-S31N inhibitors by diversifying the aromatic head groups and the hydrophobic substitutions. Toward this goal, we devised a late-stage functionalization strategy that allows us to conveniently introduce diverse hydrophobic substitutions at the last step (Scheme 1). Specifically, the Buchwald−Hartwig C−N crosscoupling reaction was employed to install various hydrophobic substitutions on the aromatic head groups (pyrimidine, pyridine, and pyrazine). The precursors (9, 12, 15, and 19) for the cross-couplings were prepared using previously optimized reductive amination reaction conditions. 26 The yield ranged from 79 to 84%. Compound 10d was synthesized directly from 2-phenylpyrimidine-5-carbaldehyde by reductive amination. The optimized conditions for Buchwald−Hartwig cross-coupling reactions for pyrimidine were found to be Pd 2 (dba) 3 (5% mol), BINAP (15% mol), and NaO t Bu (1.4 equiv) under microwave heating at 100°C in toluene for 30 min. The yields ranged from 72 to 85%. When this condition was applied to the synthesis of pyridine (2-substituted or 3-substituted) and pyrazine analogues, it also gave similar satisfactory yields. The yields for 2-substituted pyridine analogues, 3-substituted pyridine analogues, and pyrazine analogues ranged from 75 to 82%, from 75 to 81%, and from 71 to 78%, respectively. Overall, this synthesis route proved to be robust and amenable for parallel synthesis. Channel Blockage Profiling by Two-Electrode Voltage Clamp Assays. Synthesized compounds were tested for their channel blockage against the M2-S31N proton channel using the two-electrode voltage clamp (TEVC) assay. TEVC is one of the gold standard assays for studying ion channel current conductance and drug inhibition. 25 In this assay, the M2-S31N channel was expressed in the oocyte cell membrane and was activated by acidic pH (pH 5.5). All compounds were tested at 100 μM, and the channel conductance current was recorded at the 2 min time point after the application of compounds. The activity of the compound was expressed as a percentage of current inhibition. For the pyrimidine series of compounds, the intermediate compound 9, which lacks a hydrophobic substitution, had minimal M2-S31N channel inhibition (8.8 ± 1.9%) at 100 μM (Table 1) . Similar results were found for other precursors, such as compounds 12, 15, and 19, and all of them had weak M2-S31N channel inhibition (Table 1) . When a pyrrolidine substitution was introduced to the pyrimidine aromatic headgroup, compound 10a showed increased M2-S31N channel inhibition (47.8 ± 2.8%). The activity was further improved for compounds with piperidine (10b and 10c), azepane (10f), and azocane (10h and 10i) substitutions. Compound 10d with a benzene substitution was less active than the piperidine analogue (10c) (57.7 ± 1.0 versus 67.2 ± 1.5%). Compound 10e with a hydrophilic substitution, morpholine, was also much less active than the piperidine analogue (10c) (26.4 ± 3.0 versus 67.2 ± 1.5%). A hydroxyl substitution at the 3-position of adamantane was generally Table 1 . Structure−Channel Blockage Activity Relationships of M2-S31N Inhibitors a a *, Values represent the mean of three independent measurements. The data are presented as percent inhibition at 100 μM at the 2 min time point. N.T., not tested. **, Measurements were taken only once tolerated for the pyrimidine series of compounds (10b versus 10c and 10h versus 10i) except the azepane analogues (10f versus 10g). Overall, these results indicate that a hydrophobic substitution on the aromatic headgroup is required for M2-S31N inhibition. The optimal hydrophobic substitutions are piperidine, azepane, and azocane. Similar SAR results were also found for the pyridine and pyrazine series of analogues. For example, for the 2-substitued pyridine series, compounds with azepane (13c) and azocane (13d and 13e) substitutions were more potent than the piperidine analogues (13a and 13b). For the 3-substitued pyridine series, compounds with azepane (16c and 16d) and azocane (16e and 16f) substitutions were similarly more potent than the piperidine analogues (16a and 16b). The most potent compound from the pyridine series was 16d, which showed 85.8 ± 0.9% inhibition at 100 μM. For the pyrazine series, compounds with azepane substitutions (20c and 20d) outperformed piperidine analogues (20a) and azocane analogues (20e and 20f). In summary, pyrimidine, 3-substituted pyridine, and pyrazine are the more favorable aromatic head groups than 2-substituted pyridine, and azepane and azocane are the more favorable hydrophobic substitutions than pyrrolidine, piperidine, and morpholine ( Figure 2 ). When tested aganist the M2-WT channel at 100 μM drug concentration, none of the compound showed potent inhibition ( Table 1) ." Antiviral Activity of Potent Lead Compounds. As M2 is essential for viral replication, M2 channel blockers are expected to have potent antiviral activity. To test this hypothesis, we evaluated several compounds (10b, 10c, 10f, 16d, 16f, and 20c) for their antiviral activity and cytotoxicity. Compounds 10f, 16d, and 20c all had >80% M2-S31N channel inhibition at 100 μM. Compounds 10c and 16f, which had <70% M2-S31N channel inhibition at 100 μM, were also chosen to determine a correlation between the channel blockage activity and the antiviral activity. The antiviral activity was tested against the amantadine-resistant A/WSN/33 (H1N1) virus, which contains the M2-S31N mutant, using the cytopathic effect (CPE) assay. All compounds were found to display single to submicromolar EC 50 values against A/WSN/33 (H1N1), which are comparable to the antiviral efficacy of amantadine in inhibiting the WT A/Udorn/72 (H3N2) virus. 28 Moreover, there is a positive correlation between M2-S31N channel blockage activity and antiviral activity: compounds 10b, 10f, 16d, and 20c, which had more potent channel blockage activity in electrophysiological assays than compounds 10c and 16f, were also more active in the antiviral CPE assays than compounds 10c and 16f. These results are consistent with previous findings.
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As the selectivity index is critical for lead optimization, the cytotoxicity of the compounds was tested in both MDCK cells and human epithelial cells A549 (Table 2) . Compound 10b had moderate cytotoxicity, with CC 50 values of 33.9 and 72.1 μM against MDCK and A549 cells, respectively. The selectivity index greatly improved upon introduction of a hydroxyl group at the 3-position of adamantane, and the CC 50 Table 2) . Similarly, the antiviral EC 50 values of the pyridine compound 16d in inhibiting A/Switzerland/9715293/2013 (H3N2) and A/ California/07/2009 (H1N1) are 3.2 ± 0.7 and 8.7 ± 3.7 μM, respectively ( Figure 3 ). In summary, compounds 10c and 16d were found to have consistently low micromolar antiviral efficacy against several M2-S31N-containing influenza A viruses.
■ CONCLUSIONS
With the continuous prescription of oseltamivir, it will only be a matter of time before predominant flu strains become resistant to it. The alarming fact is that the oseltamivir-resistant strains have been continuously reported, and certain strains appear to adapt to the fitness of transmission among humans, which could lead to the next influenza pandemic. 29−31 In addressing this unmet medical need, we revisited the M2 proton channel and aim to develop the next generation of antivirals by targeting the M2-S31N mutant. We chose M2-S31N mutant as the drug target because it is one of the most conserved viral proteins among circulating influenza A viruses. However, it is generally assumed that M2 is not a desired antiviral drug because of the failed example of amantadine; resistance easily emerges with amantadine treatment in the case of WT viruses. However, our recent studies demonstrated that unlike amantadine, M2-S31N channel blockers have a higher genetic barrier of drug resistance that is comparable to that of oseltamivir. 32 Therefore, M2-S31N remains a high-profile antiviral drug target to combat drug resistance. In this study, we developed a late-stage diversification synthesis strategy that enabled us to expeditiously synthesize a focused library of M2-S31N inhibitors. All synthesized compounds were tested in electrophysiological assays, and potent lead compounds were further tested in antiviral assays. It was found that a hydrophobic substitution, preferentially piperidine and azepane, is required at the paraposition of the aromatic headgroup for potent M2-S31N channel blockage. A number of heterocycles such as pyridine, pyrimidine, and pyrazine are tolerated. Hydroxyl group substitution on the adamantane ring appears to lower the cytotoxicity, possibly due to reduced hydrophobicity. Potent channel blockers were also consistently found to have greater antiviral efficacy. The most potent compounds, 10c and 16d, have single-digit micromolar efficacy against all three M2-S31N-containing influenza A viruses, A/WSN/33 (H1N1), A/ Switzerland/9715293/2013 (H3N2), and A/California/07/ 2009 (H1N1). The potent antiviral efficacy, coupled with the favorable selectivity indexes, warrants further evaluation of these lead compounds in in vivo animal studies. They can be used either as monotherapy or in combination with oseltamivir to confine the outbreak of the next influenza pandemic. 33 ■ EXPERIMENTAL PROCEDURES Chemistry. All chemicals are commercially available and were used without further purification. Detailed synthesis procedures can be found in the Supporting Information for reactions described in Scheme 1. All final compounds were purified by flash column chromatography, and the purity of all compounds tested was ≥95% as determined by LC-MS. Compound characterizations ( 1 H NMR, 13 C NMR, and MS) can be found in the Supporting Information.
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Two-Electrode Voltage Clamp (TEVC) Assay. The compounds were tested in a two-electrode voltage clamp assay using Xenopus laevis frog oocytes microinjected with RNA expressing the S31N mutant of the A/M2 protein, as previously reported. 34 The potency of the inhibitors was expressed as percentage inhibition of A/M2 current observed after 2 min of incubation with 100 μM compounds at pH 5.5. All measurements were repeated three times with different oocytes.
Plaque Reduction Assay. The plaque reduction assay was performed as previously reported, 21 except MDCK cells expressing ST6Gal I were used instead of regular MDCK cells. 35 Briefly, a confluent monolayer of ST6Gal MDCK cells was incubated with ∼100 pfu virus samples in DMEM with 0.5% BSA for 1 h at 4°C and then at 37°C for 1 h. The inoculums were removed, and the cells were washed with phosphate-buffered saline (PBS). The cells were then overlaid with DMEM containing 1.2% Avicel microcrystalline cellulose (FMC BioPolymer, Philadelphia, PA, USA) and NAT (2.0 μg/ mL). To examine the effect of the compounds on plaque formation, the overlay medium was supplemented compounds at testing concentration. At 2 days after infection, the monolayers were fixed and stained with crystal violet dye solution (0. Cytotoxicity Assay and Cytopathic Effect Assay. Evaluation of the cytotoxicity of compounds and the efficacy of compounds against influenza-induced cytopathic effect was carried out using neutral red uptake assay. 36 Briefly, 80,000 cells/mL MDCK cells in DMEM supplemented with 10% FBS and 100 U/mL penicillin−streptomycin were dispensed into 96-well cell culture plates at 100 μL/well. Twenty-four hours later, the growth medium was removed and washed with 100 μL of PBS buffer; then for the cytotoxicity assay, 200 μL of fresh DMEM (no FBS) containing serially diluted compounds was added to each well, and for the cytopathic effect assay, 200 μL of fresh DMEM containing 100 pfu of A/WSN/33 influenza virus, 2 μg/mL NAT, and serially diluted compounds was added to each well. After 48 h of incubation at 37°C with 5% CO 2 in a CO 2 incubator, the medium was removed and replaced with 100 μL of DMEM containing 40 μg/mL neutral red for 4 h 37°C. The amount of neutral red taken up was determined at an absorbance of 540 nm using a Multiskan FC microplate photometer (Fisher Scientific). The EC 50 
